How Medical Cannabis Is Grown in Controlled Environments

The Importance of Controlled Environment Agriculture in Cannabis

• Medical cannabis requires consistent, reproducible growing conditions to ensure pharmaceutical-grade product quality; outdoor cultivation cannot meet the contamination and consistency standards required.
• Controlled environment agriculture (CEA) facilities for medical cannabis use indoor grow rooms or glasshouses with fully managed temperature, humidity, CO₂, light spectrum and irrigation.
• All EU-GMP certified cannabis cultivators operate within CEA facilities where every environmental variable is logged, monitored and documented as part of the batch record.
• CEA allows cultivators to run multiple harvests per year regardless of season, ensuring consistent supply to UK pharmacies and patients throughout the year.

The move to fully controlled indoor cultivation is not a preference but a regulatory requirement for any cultivator seeking EU-GMP certification and the right to supply the UK medical market.

Light, Temperature and Humidity Management

• Cannabis growth is photoperiod-sensitive; CEA facilities use precisely timed LED or HPS lighting arrays to control vegetative growth and trigger flowering on schedule.
• Temperature is typically maintained between 20°C and 28°C during the light cycle and slightly cooler during dark periods to optimise resin production and terpene expression.
• Relative humidity is maintained at 40–70% during vegetative growth and reduced to 40–50% during flowering to reduce mould risk (Botrytis is the primary pathogen of concern).
• HVAC systems in EU-GMP cannabis facilities are pharmaceutical-grade, with HEPA filtration, positive pressure zoning and continuous air exchange monitoring.

Precision environmental management is the foundation of consistent cannabinoid and terpene profiles; deviations in any parameter can alter the pharmacological composition of the final product.

Substrate, Water and Nutrient Management

• Medical cannabis is grown in sterile, pH-neutral substrates — typically rockwool, coco coir or hydroponic systems — to eliminate soil-borne pathogens and standardise nutrient delivery.
• Irrigation systems in CEA facilities deliver precise volumes of nutrient solution at regulated intervals; run-off testing confirms root zone pH and electrical conductivity are within specification.
• Fertilisers used in EU-GMP facilities must be food-grade or pharmaceutical-grade; the use of prohibited pesticides or excessive heavy metal inputs is tested at harvest and must not exceed regulatory limits.
• Water quality is tightly controlled; reverse osmosis or deionised water is standard to remove chlorine, chloramine and heavy metals before nutrient addition.

Every input into a medical cannabis CEA facility — from seed to nutrient to substrate — is selected and documented to ensure the final product meets pharmaceutical traceability requirements.

Quality Monitoring During Cultivation

• EU-GMP facilities conduct in-process checks throughout cultivation: weekly pathogen swabs of growing surfaces, leaf tissue analysis for nutrient status and visual pest inspections.
• Batch records documenting every environmental event, input and observation are maintained throughout the cultivation cycle and are subject to quality management review before harvest.
• Genetic consistency is maintained through verified mother plant programmes or tissue culture; each batch is traceable to a specific genetic lineage with documented cannabinoid and terpene profiles.
• At harvest, representative samples from each batch are retained for full panel testing including cannabinoid potency, pesticide residues, heavy metals, mycotoxins and microbial contamination.

The documentation culture in EU-GMP cannabis cultivation mirrors pharmaceutical manufacturing: every decision is recorded, every deviation is investigated and every batch must pass full quality release testing before it leaves the facility.